Haleon (LON:HLN) Given New GBX 500 Price Target at Berenberg Bank

Key Points

• Berenberg Bank has reduced its target price for Haleon stock from GBX 503 ($6.76) to GBX 500 ($6.72), while maintaining a "buy" rating, suggesting a potential upside of 41.08% from the current price.
• The stock recently opened at GBX 354.40 ($4.76), with a market cap of £31.99 billion, and is trading near its one-year low of GBX 346.10 ($4.65).
• Haleon reported earnings per share of GBX 8.90 ($0.12) for the most recent quarter and analysts expect an average of 19.50 earnings per share for the current fiscal year.

Haleon (LON:HLN - Free Report) had its target price cut by Berenberg Bank from GBX 503 ($6.83) to GBX 500 ($6.79) in a research report sent to investors on Friday morning, Marketbeat.com reports. They currently have a buy rating on the stock.

HLN has been the subject of several other reports. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of Haleon in a research note on Friday, August 1st. Royal Bank Of Canada reissued a "sector perform" rating and issued a GBX 370 ($5.02) price target on shares of Haleon in a report on Thursday, July 31st.

Haleon Stock Performance

Shares of HLN traded up GBX 4 ($0.05) during trading hours on Friday, hitting GBX 359 ($4.88). The stock had a trading volume of 11,390,435 shares, compared to its average volume of 25,045,436. The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84. The firm has a 50-day moving average price of GBX 372.41 and a 200 day moving average price of GBX 384.11. Haleon has a fifty-two week low of GBX 346.10 ($4.70) and a fifty-two week high of GBX 419.50 ($5.70). The firm has a market capitalization of £32.40 billion, a price-to-earnings ratio of 30.19, a PEG ratio of 1.49 and a beta of 0.19.

Haleon (LON:HLN - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported GBX 8.90 ($0.12) earnings per share (EPS) for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. As a group, research analysts anticipate that Haleon will post 19.5033282 EPS for the current year.

Insider Buying and Selling at Haleon

In other news, insider Dawn Allen sold 64,329 shares of the company's stock in a transaction on Monday, June 30th. The shares were sold at an average price of GBX 376 ($5.11), for a total transaction of £241,877.04 ($328,458.77). Also, insider Blathnaid Bergin bought 6,145 shares of the company's stock in a transaction dated Friday, May 16th. The shares were acquired at an average cost of GBX 404 ($5.49) per share, with a total value of £24,825.80 ($33,712.38). 10.74% of the stock is currently owned by insiders.

Haleon Company Profile

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.